The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Fabry disease revisited: Management and treatment recommendations for adult patients
Open accessAbstract
Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene leading to deficient α-galactosidase A activity, glycosphingolipid accumulation, and life-threatening complications. Phenotypes vary from the "classic" phenotype, with pediatric onset and multi-organ involvement, to later-onset, a predominantly cardiac phenotype. Manifestations are diverse in female patients in part due to variations in residual enzyme activity and X chromosome inactivation patterns. Enzyme replacement therapy (ERT) and adjunctive treatments can provide significant clinical benefit. However, much of the current literature reports outcomes after late initiation of ERT, once substantial organ damage has already occurred. Updated monitoring and treatment guidelines for pediatric patients with Fabry disease have recently been published. Expert physician panels were convened to develop updated, specific guidelines for adult patients. Management of adult patients depends on 1) a personalized approach to care, reflecting the natural history of the specific disease phenotype; 2) comprehensive evaluation of disease involvement prior to ERT initiation; 3) early ERT initiation; 4) thorough routine monitoring for evidence of organ involvement in non-classic asymptomatic patients and response to therapy in treated patients; 5) use of adjuvant treatments for specific disease manifestations; and 6) management by an experienced multidisciplinary team.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
Self-citationMacLeod, A. M. (2009) · Kidney International · Cited by 2,218
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450102 · Cited by 1,559
Self-citationEnzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial
Schiffmann, R., Kopp, J. B., Austin III, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., & Brady, R. O. (2001) · JAMA · doi:10.1001/jama.285.21.2743 · Cited by 1,302
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
Self-citationMacDermot, K. D., Holmes, A., & Miners, A. H. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.11.769 · Cited by 681
Agalsidase-Beta Therapy for Advanced Fabry Disease: A Randomized Trial
Banikazemi, M., Bultas, J., Waldek, S., Wilcox, W. R., Whitley, C. B., McDonald, M., Finkel, R., Packman, S., Bichet, D. G., Warnock, D. G., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-2-200701160-00148 · Cited by 569
Self-citationTreatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
Germain, D. P., Hughes, D. A., Nicholls, K., Bichet, D. G., Giugliani, R., Wilcox, W. R., Feliciani, C., Shankar, S. P., Ezgu, F., Amartino, H., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510198 · Cited by 555
Self-citationFemales with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
Wilcox, W. R., Oliveira, J. P., Hopkin, R. J., Ortiz, A., Banikazemi, M., Feldt-Rasmussen, U., Sims, K., Waldek, S., Pastores, G. M., Lee, P., et al. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.09.013 · Cited by 544
Self-citationGermain, D. P., Waldek, S., Banikazemi, M., Bushinsky, D. A., Charrow, J., Desnick, R. J., Lee, P., Loew, T., Vedder, A. C., Abichandani, R., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080816 · Cited by 438
Self-citationX‐chromosome inactivation in female patients with Fabry disease
Echevarria, L., Benistan, K., Toussaint, A., Dubourg, O., Hagege, A. A., Eladari, D., Jabbour, F., Beldjord, C., De Mazancourt, P., & Germain, D. P. (2016) · Clinical Genetics · doi:10.1111/cge.12613 · Cited by 424
Self-citationCharacterization of Classical and Nonclassical Fabry Disease: A Multicenter Study
Arends, M., Wanner, C., Hughes, D., Mehta, A., Oder, D., Watkinson, O. T., Elliott, P. M., Linthorst, G. E., Wijburg, F. A., Biegstraaten, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016090964 · Cited by 416
Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement
Eng, C. M., Germain, D. P., Banikazemi, M., Warnock, D. G., Wanner, C., Hopkin, R. J., Bultas, J., Lee, P., Sims, K., Brodie, S. E., et al. (2006) · Genetics in Medicine · doi:10.1097/01.gim.0000237866.70357.c6 · Cited by 411
Self-citationLong-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease
Wilcox, W. R., for the International Fabry Disease Study Group, Banikazemi, M., Guffon, N., Waldek, S., Lee, P., Linthorst, G. E., Desnick, R. J., & Germain, D. P. (2004) · The American Journal of Human Genetics · doi:10.1086/422366 · Cited by 404
Self-citationLinhart, A., Kampmann, C., Zamorano, J. L., Sunder-Plassmann, G., Beck, M., Mehta, A., Elliott, P. M., & on behalf of European FOS Investigators (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm153 · Cited by 397
Self-citationHughes, D. A., Nicholls, K., Shankar, S. P., Sunder-Plassmann, G., Koeller, D., Nedd, K., Vockley, G., Hamazaki, T., Lachmann, R., Ohashi, T., et al. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-104178 · Cited by 386
Self-citationTen-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
Germain, D. P., Charrow, J., Desnick, R. J., Guffon, N., Kempf, J., Lachmann, R. H., Lemay, R., Linthorst, G. E., Packman, S., Scott, C. R., et al. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102797 · Cited by 368
Self-citationHwu, W.-L., Chien, Y.-H., Lee, N.-C., Chiang, S.-C., Dobrovolny, R., Huang, A.-C., Yeh, H.-Y., Chao, M.-C., Lin, S.-J., Kitagawa, T., et al. (2009) · Human Mutation · doi:10.1002/humu.21074 · Cited by 361
Self-citationWaldek, S., Patel, M. R., Banikazemi, M., Lemay, R., & Lee, P. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e3181bb05bb · Cited by 353
Self-citationSims, K., Politei, J., Banikazemi, M., & Lee, P. (2009) · Stroke · doi:10.1161/strokeaha.108.526293 · Cited by 342
Self-citation2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., Mahrholdt, H., et al. (2014) · Kardiologia Polska · doi:10.5603/kp.2014.0212 · Cited by 341
Wang, R. Y., Lelis, A., Mirocha, J., & Wilcox, W. R. (2007) · Genetics in Medicine · doi:10.1097/gim.0b013e31802d8321 · Cited by 305
Self-citationNatural history of Fabry disease in females in the Fabry Outcome Survey
Deegan, P. B., Baehner, A. F., Barba Romero, M.-Á., Hughes, D. A., Kampmann, C., & Beck, M. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.036327 · Cited by 304
Mechtler, T. P., Stary, S., Metz, T. F., De Jesús, V. R., Greber-Platzer, S., Pollak, A., Herkner, K. R., Streubel, B., & Kasper, D. C. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61266-x · Cited by 297
Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta
Linthorst, G. E., Hollak, C. E. M., Donker-Koopman, W. E., Strijland, A., & Aerts, J. M. F. G. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00924.x · Cited by 282
Schiffmann, R., Ries, M., Timmons, M., Flaherty, J. T., & Brady, R. O. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi152 · Cited by 269
Lee, K. (2003) · Glycobiology · doi:10.1093/glycob/cwg034 · Cited by 253
Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals
Wang, R. Y., Bodamer, O. A., Watson, M. S., & Wilcox, W. R. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e318211a7e1 · Cited by 244
Self-citationAgalsidase Benefits Renal Histology in Young Patients with Fabry Disease
Tøndel, C., Bostad, L., Larsen, K. K., Hirth, A., Vikse, B. E., Houge, G., & Svarstad, E. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012030316 · Cited by 237
Weidemann, F., Niemann, M., Störk, S., Breunig, F., Beer, M., Sommer, C., Herrmann, S., Ertl, G., & Wanner, C. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12077 · Cited by 223
Self-citationOrtiz, A., Oliveira, J. P., Waldek, S., Warnock, D. G., Cianciaruso, B., Wanner, C., & on behalf of the Fabry Registry (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm848 · Cited by 221
Self-citationBenjamin, E. R., Della Valle, M. C., Wu, X., Katz, E., Pruthi, F., Bond, S., Bronfin, B., Williams, H., Yu, J., Bichet, D. G., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.122 · Cited by 213
Self-citationvan der Tol, L., Smid, B. E., Poorthuis, B. J. H. M., Biegstraaten, M., Deprez, R. H. L., Linthorst, G. E., & Hollak, C. E. M. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2013-101857 · Cited by 199
Hopkins, P. V., Campbell, C., Klug, T., Rogers, S., Raburn-Miller, J., & Kiesling, J. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2014.09.023 · Cited by 199
Stockman, J. A. (2013) · Yearbook of Pediatrics · doi:10.1016/j.yped.2012.03.067 · Cited by 198
Schiffmann, R., Hughes, D. A., Linthorst, G. E., Ortiz, A., Svarstad, E., Warnock, D. G., West, M. L., Wanner, C., Bichet, D. G., Christensen, E. I., et al. (2017) · Kidney International · doi:10.1016/j.kint.2016.10.004 · Cited by 194
Self-citationFabry disease and the skin: data from FOS, the Fabry outcome survey
Orteu, C. H., Jansen, T., Lidove, O., Jaussaud, R., Hughes, D. A., Pintos-Morell, G., Ramaswami, U., Parini, R., Sunder-Plassman, G., Beck, M., et al. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08002.x · Cited by 179
Warnock, D. G., Ortiz, A., Mauer, M., Linthorst, G. E., Oliveira, J. P., Serra, A. L., Marodi, L., Mignani, R., Vujkovac, B., Beitner-Johnson, D., et al. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr420 · Cited by 176
Self-citationNewborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy
Burlina, A. B., Polo, G., Salviati, L., Duro, G., Zizzo, C., Dardis, A., Bembi, B., Cazzorla, C., Rubert, L., Zordan, R., et al. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0098-3 · Cited by 174
Self-citationCardiovascular Events in Patients With Fabry Disease
Patel, M. R., Cecchi, F., Cizmarik, M., Kantola, I., Linhart, A., Nicholls, K., Strotmann, J., Tallaj, J., Tran, T. C., West, M. L., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.018 · Cited by 173
Self-citationOnset and progression of the Anderson–Fabry disease related cardiomyopathy
Kampmann, C., Linhart, A., Baehner, F., Palecek, T., Wiethoff, C. M., Miebach, E., Whybra, C., Gal, A., Bultas, J., & Beck, M. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.03.007 · Cited by 173
Self-citationSmid, B. E., van der Tol, L., Cecchi, F., Elliott, P. M., Hughes, D. A., Linthorst, G. E., Timmermans, J., Weidemann, F., West, M. L., Biegstraaten, M., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.001 · Cited by 170
Self-citationAgalsidase Alfa and Kidney Dysfunction in Fabry Disease
West, M., Nicholls, K., Mehta, A., Clarke, J. T. R., Steiner, R., Beck, M., Barshop, B. A., Rhead, W., Mensah, R., Ries, M., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008080870 · Cited by 162
Lukas, J., Giese, A.-K., Markoff, A., Grittner, U., Kolodny, E., Mascher, H., Lackner, K. J., Meyer, W., Wree, P., Saviouk, V., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003632 · Cited by 160
Cerebrovascular Involvement in Fabry Disease: Current Status of Knowledge
Kolodny, E., Fellgiebel, A., Hilz, M. J., Sims, K., Caruso, P., Phan, T. G., Politei, J., Manara, R., & Burlina, A. (2015) · Stroke · doi:10.1161/strokeaha.114.006283 · Cited by 159
Self-citationOrtíz, A., Abiose, A. K., Bichet, D. G., Cabrera, G. H., Charrow, J., Germain, D. P., Hopkin, R. J., Jovanović, A., Linhart, A., Maruti, S. S., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103486 · Cited by 145
Self-citationEnd-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry
Ortíz, A., Cianciaruso, B., Cizmarik, M., Germain, D. P., Mignani, R., Oliveira, J. P., Villalobos, J., Vujkovac, B., Waldek, S., Wanner, C., et al. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp554 · Cited by 138
Self-citationSerum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
Lenders, M., Stypmann, J., Duning, T., Schmitz, B., Brand, S.-M., & Brand, E. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014121226 · Cited by 133
Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment
Politei, J. M., Bouhassira, D., Germain, D. P., Goizet, C., Guerrero-Sola, A., Hilz, M. J., Hutton, E. J., Karaa, A., Liguori, R., Üçeyler, N., et al. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12542 · Cited by 131
Self-citationThe management and treatment of children with Fabry disease: A United States-based perspective
Hopkin, R. J., Jefferies, J. L., Laney, D. A., Lawson, V. H., Mauer, M. S., Taylor, M. R. G., & Wilcox, W. R. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.10.007 · Cited by 121
Self-citationSakuraba, H., Murata-Ohsawa, M., Kawashima, I., Tajima, Y., Kotani, M., Ohshima, T., Chiba, Y., Takashiba, M., Jigami, Y., Fukushige, T., et al. (2005) · Journal of Human Genetics · doi:10.1007/s10038-005-0342-9 · Cited by 112
Quality of life in patients with Fabry disease: a systematic review of the literature
Arends, M. L., Hollak, C. E. M., & Biegstraaten, M. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0296-8 · Cited by 111
Newborn screening for lysosomal storage disorders
Matern, D., Gavrilov, D. K., Oglesbee, D., Raymond, K., Rinaldo, P., & Tortorelli, S. (2015) · Seminars in Perinatology · doi:10.1053/j.semperi.2015.03.005 · Cited by 109
Clinical and genetic predictors of major cardiac events in patients with Anderson–Fabry Disease
Patel, V. H., O’Mahony, C., Hughes, D. A., Rahman, M. S., COATS, C. J., Murphy, E., Lachmann, R., Mehta, A. B., & Elliot, P. M. (2015) · Heart · doi:10.1136/heartjnl-2014-306782 · Cited by 105
Electrocardiographic Changes and Arrhythmia in Fabry Disease
Namdar, M. (2016) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2016.00007 · Cited by 102
Diagnosis of Fabry Disease via Analysis of Family History
Laney, D. A., & Fernhoff, P. M. (2008) · Journal of Genetic Counseling · doi:10.1007/s10897-007-9128-x · Cited by 100
Self-citationCognitive dysfunction and depression in Fabry disease: a systematic review
Bolsover, F., Murphy, E., Lisa Cipolotti, A., Werring, D. J., & Lachmann, R. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9643-x · Cited by 93
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults
Ortíz, A., Oliveira, J. P., Wanner, C., Brenner, B. M., Waldek, S., & Warnock, D. G. (2008) · Nature Reviews Nephrology · doi:10.1038/ncpneph0806 · Cited by 80
Self-citationFabry disease, enzyme replacement therapy and the significance of antibody responses
Deegan, P. B. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9400-y · Cited by 74
Niemann, M., Rolfs, A., Giese, A., Mascher, H. J., Breunig, F., Ertl, G., Wanner, C., & Weidemann, F. (2012) · JIMD Reports · doi:10.1007/8904_2012_154 · Cited by 65
Self-citationWeidemann, F., Maier, S. K. G., Störk, S., Brunner, T. B., Liu, D., Hu, K., Seydelmann, N., Schneider, A., Becher, J., Canaan‐Kühl, S., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.04.033 · Cited by 63
Self-citationLakomá, J., Rimondini, R., Donadio, V. A., Liguori, R., & Caprini, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108641 · Cited by 62
Three-dimensional face shape in Fabry disease
Cox‐Brinkman, J., Vedder, A. C., Hollak, C. E. M., Richfield, L., Mehta, A. B., Orteu, K., Wijburg, F. A., & Hammond, P. (2007) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201798 · Cited by 56
BODENSTEINER, D. C., Scott, C. R., Sims, K. B., Shepherd, G. M., Cintron, R. D., & Germain, D. P. (2008) · Genetics in Medicine · doi:10.1097/gim.0b013e318170f868 · Cited by 52
Self-citationLinthorst, G. E., Germain, D. P., Hollak, C. E. M., Hughes, D. A., Rolfs, A., Wanner, C., & Mehta, A. B. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.11.155 · Cited by 47
Self-citationGöker-Alpan, Ö., Gambello, M. J., Maegawa, G. H. B., Nedd, K. J., Gruskin, D. J., Blankstein, L. A., & Weinreb, N. J. (2015) · JIMD Reports · doi:10.1007/8904_2015_483 · Cited by 30
Nakano, S., Tsukimura, T., Togawa, T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128351 · Cited by 19
Cited by
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Self-citationPharmacological targeting of endoplasmic reticulum stress in disease
Marciniak, S. J., Chambers, J. E., & Ron, D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00320-3 · Cited by 520
Cardiac Involvement in Fabry Disease
Pieroni, M., Moon, J. C., Arbustini, E., Barriales-Villa, R., Camporeale, A., Vujkovac, A. C., Elliott, P. M., Hagege, A., Kuusisto, J., Linhart, A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.024 · Cited by 340
Self-citationLysosomal storage disease overview
Sun, A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.39 · Cited by 271
Current and Investigational Therapeutics for Fabry Disease
Felis, A., Whitlow, M., Kraus, A., Warnock, D. G., & Wallace, E. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2019.11.013 · Cited by 100
Self-citation
Metadata
- Authors
- Ortiz, A., Germain, D. P., Desnick, R. J., Politei, J., Mauer, M., Burlina, A., Eng, C., Hopkin, R. J., Laney, D., Linhart, A., Waldek, S., Wallace, E., Weidemann, F., & Wilcox, W. R.
- Venue
- Molecular Genetics and Metabolism
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 123
- Issue
- 4
- Pages
- 416-427
- ISSN
- 1096-7192 (ISSN-L)
- OpenAlex
- W2789753965
- Cited by
- 650
- References
- 67
- FWCI
- 32.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.